Mechanism of Action of Januvia (Sitagliptin)

---

Introduction

Januvia (sitagliptin) is an oral dipeptidyl peptidase‑4 (DPP‑4) inhibitor used to improve glycemic control in type 2 diabetes mellitus (T2DM). It enhances incretin levels, thereby increasing insulin secretion and lowering glucagon in a glucose-dependent manner.

---

Step-by-Step Mechanism of Action

1. Selective inhibition of DPP‑4 enzyme
   Sitagliptin irreversibly binds to and inhibits DPP‑4, preventing the degradation of incretin hormones GLP‑1 and GIP.
2. Increased levels of active GLP‑1 and GIP
   With DPP‑4 suppressed, endogenous GLP‑1 and GIP remain active longer, boosting their physiological effects.
3. Enhanced glucose-dependent insulin secretion
   Elevated incretins stimulate β‑cells to release insulin when blood glucose is elevated.
4. Suppressed glucagon secretion
   Active GLP‑1 reduces α‑cell glucagon release, decreasing hepatic glucose output.
5. Glucose-dependent mechanism minimizes hypoglycemia risk
   This pathway reduces glucose only when blood levels are high, offering a safer profile versus some other antidiabetic agents.

---

Pharmacokinetic Parameters

Parameter	Value
Route	Oral (tablet)
Bioavailability	~87%
Time to Peak (Tmax)	~1–4 hours
Protein Binding	Minimal (~38%)
Metabolism	Excreted largely unchanged via kidneys (~79%)
Half-life	~12.4 hours
Excretion	Primarily renal

---

Clinical Uses

• Monotherapy in T2DM when diet and exercise alone are insufficient
• Combination therapy with metformin, sulfonylureas, or insulin
• Particularly useful in patients at risk of hypoglycemia or needing once-daily dosing

---

Adverse Effects

• Typically well tolerated
• Possible nasopharyngitis, headache, upper respiratory symptoms
• Rare: pancreatitis, hypersensitivity reactions
• Low risk of hypoglycemia when used alone

---

Comparative Analysis

Drug	Incretin Mechanism	Hypoglycemia Risk	Weight Effect	Dosing
Sitagliptin	DPP‑4 inhibition	Low	Weight neutral	Once daily
Saxagliptin	DPP‑4 inhibition	Low	Weight neutral	Once daily
GLP‑1 agonists	GLP‑1 receptor agonism	Low–moderate	Weight loss	Daily or weekly

---

MCQs

1. Januvia inhibits which enzyme?
   a) SGLT2 b) DPP‑4 c) α‑glucosidase d) CYP3A4
   Answer: b) DPP‑4
2. Inhibition increases which hormones?
   a) Insulin only b) GLP‑1 and GIP c) Glucagon only d) Amylin & somatostatin
   Answer: b) GLP‑1 and GIP
3. The glucose-lowering effect is:
   a) Constant b) Glucose-dependent c) Hypoglycemia-prone d) Insulin-independent
   Answer: b) Glucose-dependent
4. Sitagliptin is primarily excreted via:
   a) Feces b) Urine c) Bile d) Sweat
   Answer: b) Urine
5. A rare but serious side effect is:
   a) Hypoglycemia b) Pancreatitis c) Hypothyroidism d) Bladder cancer
   Answer: b) Pancreatitis
6. Protein binding is approximately:
   a) 10% b) 38% c) 80% d) 99%
   Answer: b) 38%
7. DPP‑4 inhibitors differ from GLP‑1 agonists by:
   a) Oral vs injection b) Cost only c) Efficacy only d) Indication only
   Answer: a) Oral vs injection
8. Combination with sulfonylureas increases risk of:
   a) Pancreatitis b) Heart failure c) Hypoglycemia d) Weight gain
   Answer: c) Hypoglycemia
9. Dose scheduling is:
   a) Multiple times daily b) Once daily c) Every other day d) Weekly
   Answer: b) Once daily
10. Sitagliptin therapy is least likely to cause:
    a) Hypoglycemia b) Weight gain c) Nasopharyngitis d) Pancreatitis
    Answer: a) Hypoglycemia
11. Onset of action occurs within:
    a) Minutes b) Hours c) Days d) Weeks
    Answer: b) Hours
12. Compared to saxagliptin, sitagliptin has:
    a) Higher potency b) Lower potency c) Similar profile d) Different mechanism
    Answer: c) Similar profile
13. Sitagliptin should be dose-adjusted for:
    a) Liver disease b) Renal impairment c) Hypothyroidism d) Pregnancy
    Answer: b) Renal impairment
14. Weight effect of sitagliptin is:
    a) Weight gain b) Weight loss c) Weight neutral d) Unknown
    Answer: c) Weight neutral
15. Sitagliptin carries risk of heart failure?
    a) High risk b) Moderate risk c) Low risk except with saxagliptin d) No risk
    Answer: c) Low risk except with saxagliptin

---

FAQs

1. Does sitagliptin cause weight gain?
No—it’s generally weight neutral, making it suitable for patients where weight gain is a concern.

2. When should renal function be checked?
Assess baseline renal function and adjust dose in CKD stages 3–5.

3. Is sitagliptin safe with insulin?
Yes, but monitor for hypoglycemia, especially when combined with insulin or sulfonylureas.

4. How fast does it lower blood sugar?
HbA₁c reductions typically occur within 8–12 weeks of therapy.

5. Are there cardiovascular benefits?
Neutral cardiovascular outcomes have been observed; it’s safe but not proven to reduce CV events.

---

References

• Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th Edition
• KD Tripathi. Essentials of Medical Pharmacology, 8th Edition
• DrugBank: Sitagliptin pharmacology summary
• StatPearls: Sitagliptin and other DPP‑4 inhibitors
• PubMed review: Cardiovascular safety of sitagliptin